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Abstract
Personal genome testing is offered via the internet directly to consumers. Most tests that are currently offered use
data from genome-wide scans to predict risks for multiple common diseases and traits. The utility of these tests is
limited, predominantly because they lack predictive ability and clear benefits for disease prevention that are speci-
fic for genetic risk groups. In the near future, personal genome tests will likely be based on whole genome
sequencing, but will these technological advances increase the utility of personal genome testing? Whole genome
sequencing theoretically provides information about the risks of both monogenic and complex diseases, but the
practical utility remains to be demonstrated. The utility of testing depends on the predictive ability of the test, the
likelihood of actionable test results, and the options available for the reduction of risks. For monogenic diseases,
the likelihood of known mutations will be extremely low in the general population and it will be a challenge to
recognize new causal variants among all rare variants that are found using sequencing. For complex diseases, the
predictive ability of genetic tests will be mainly restricted by the heritability of the disease, but also by the genetic
complexity of the disease etiology, which determines the extent to which the heritability can be understood. Given
that numerous genetic and non-genetic risk factors interact in the causation of complex diseases, the predictive
ability of genetic models will likely remain modest. Personal genome testing will have minimal benefits for indivi-
dual consumers unless major breakthroughs are made in the near future.
An increasing number of companies are offering health-
related personal genome testing via the internet directly
to consumers. Over time, these products have evolved
from testing a few variants for a single health outcome to
testing hundreds of thousands genetic variants genome-
wide for multiple outcomes simultaneously. These tests
provide information about predisposition to drug
response and risk predictions for a variety of diseases.
For example, DeCODEme is currently predicting risks
for 50 different diseases, traits and medication responses,
Navigenics for 40 and 23 and Me for 66. The outcomes
predicted range from various cancers, to Alzheimer dis-
ease, to Warfarin response and eye color (accessed 14
July 2010). The utility of these tests is far from clear, not
in the least because the predictive ability is still limited
for most diseases, and risk predictions remain subject to
change as long as new variants are being discovered [1-4].
To facilitate the discovery of new variants, next-
generation whole genome sequencing is increasingly
utilized in genetic research. The arrays used for genome
wide scans include a very large but finite number of
common variants covering the genome based on the
principle of linkage disequilibrium. In contrast, whole
genome sequencing documents the entire genome, base
pair by base pair, and thus comprises more DNA varia-
tions, such as rare variants, copy number and structural
variations with potentially larger effects on clinically
relevant outcomes. Whole genome sequencing will
be instrumental to discover more common variants
implicated in complex outcomes, but may also reveal
rare causal genetic variants for monogenic diseases that
are private to specific populations or even to persons.
Because whole genome sequencing gives a more com-
plete coverage, it is beyond doubt that companies will
consider the technique to predict predisposition to drug
response and risks of complex and monogenic diseases.
Whole genome sequencing is still rather expensive, par-
ticularly to obtain the high analytic validity that is
required to make predictions at the individual level, but
costs are decreasing rapidly. Yet, the question is whether
these technological advances will also increase the utility
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whether whole genome sequencing will be able to
increase the predictive ability and the expected benefits
of testing.
Predictive ability of personal genome testing
In the first place, the utility is determined by the ques-
tion “will the personal genome testing have appreciable
predictive ability to tell the future development of dis-
ease?” [5]. The predictive ability is evaluated for each
disease separately and may differ considerably between
diseases tested within the same scan, particularly
between monogenic and complex traits. The difference
in the predictive ability between monogenic and com-
plex diseases is explained by two aspects of the genetic
etiology, namely the heritability and the genetic com-
plexity of the disease.
Monogenic diseases such as Huntington disease and
cystic fibrosis are highly heritable. Although there may
be multiple genetic and non-genetic factors influencing
prognosis, mutations in a limited number of specific
genes by themselves are sufficient causes of disease and
testing the absence or presence of these mutations accu-
rately predicts future disease development in families.
Complex diseases on the other hand are caused by an
intricate interplay of many genetic and non-genetic fac-
tors, such as smoking, alcohol consumption, diet and
physical activity. The predictive ability of genetic risk
models is determined by the combined effect of all
genetic risk factors tested, and therefore indirectly by
the frequency and effects of all variants included in the
model. Empirical studies so far have shown that the pre-
dictive ability for most complex diseases is still moder-
ate at best, which is for a large part explained by the
relatively limited number of low-risk variants that have
been discovered so far [6]. But even if all genetic var-
iants were discovered in the future, still the predictive
ability would be restricted by the fact that complex dis-
eases are only partially heritable. Table 1 shows the
wide range of heritability estimates that is observed for
complex diseases and traits, ranging from 22% for hap-
piness to >99% for eye color. Figure 1 illustrates how
the heritability relates to the maximum discriminative
accuracy that can be obtained when all common and
rare variants that constitute the heritability are identified
[7,8]. This figure shows that theoretically an almost per-
fect genetic test will be possible for type 1 diabetes, but
that for type 2 diabetes with a heritability of 26% and an
estimated disease risk between 15-25% the discrimina-
tive accuracy will remain moderate.
Although the predictive ability of a genetic test for
type 2 diabetes can become comparable to that of cur-
rent non-genetic risk prediction models, this is only
achieved when all genetic variants are identified.
Underlying Figure 1 is the assumption that the total
heritability can be explained. Whether this is a realistic
assumption depends on the second major determinant:
the complexity of the genetic etiology. It will be difficult
to completely tease out genetic etiologies when there
are many low-risk genetic variants implicated, such as
the hundred that have been identified for blood choles-
terol. These variants may interact with each other and
with other non-genetic risk factors in many different
ways. We still have little knowledge of the interactions
that are anticipated from a biological perspective. So far,
sophisticated genetic models that did consider interac-
tions have not outperformed simple additive models
[9,10], but these studies have most likely lacked the
power to investigate even two-factor interactions. Very
complex interactions involving multiple genetic and
non-genetic factors have been beyond the scope statisti-
cally and computationally, because increased or
decreased risks due to complex interactions are difficult
to detect. When ten variants are interacting, all cases
and controls in epidemiological studies will have unique
genetic profiles, making it impossible to accurately quan-
tify risks of disease for specific combinations of variants
[6]. And when more than 20 variants are interacting,
even the world population may not be large enough to
determine the risks for specific genetic profiles. Unless
Table 1 Heritability estimates of various complex
diseases and traits
Disease or trait Heritability Reference
Eye color > 99% [18]
Type 1 diabetes 88% [19]
Schizophrenia 81% [20]
Alzheimer’s disease 79% [21]
Height 70-87% (m), 68-85% (v) [22]
Obesity 65-84% (m), 64-79% (w) [23]
Smoking persistence 59% (m), 46% (w) [24]
Anorexia nervosa 56% [25]
Rheumatoid arthritis 53-65% [26]
Panic disorder 43% [27]
Prostate cancer 42% [28]
Migraine 40-50% [29]
Heart attack 38% (m), 57% (w) [30]
Smoking initiation 37% (m), 55% (w) [24]
Depression 37% [31]
Colorectal cancer 35% [28]
Anxiety disorder 32% [27]
Homosexuality 30% (m), 50-60% (w) [32]
Breast cancer 27% [28]
Type 2 diabetes 26% [33]
Lung cancer 26% [28]
Happiness 22% (m), 41% (w) [34]
Heritability and frequency estimates are obtained from published studies and
meta-analyses. m = men, w = women.
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genetic risk factors is correct, these simple examples
show that the more complex the genetic etiology of a
trait, the less likely it is that the genetic contribution
will be fully understood in all its complexity.
The impact of heritability and genetic complexity on
the potential predictive ability of diseases is outlined in
Figure 2. When diseases are highly heritable and have a
simple genetic etiology, e.g., as in monogenetic disorders,
genetic testing will be accurate and very predictive.
Whether these variants are mutations, haplotypes, copy
number variations, insertion/deletions, or even missing
or extra copies of an entire chromosome, the presence of
the variants means that one will develop the disease and
the absence that one will not. Also traits that are predo-
minantly determined by one or a few variants, such as
human eye color, may be predicted with relatively high
accuracy [11]. When diseases are only partially influenced
by genetic factors and the heritability is in the lower
ranges, the predictive ability of tests that consider genetic
variants only will never be very accurate when non-
genetic risk factors are not included in the test. There are
however examples of traits with low heritability and
simple genetic etiology for which genetic testing may be
clinically relevant. These include genetic effects on
responses to medication, where one or a few variants,
e.g., in the cytochrome P450 genes, have a large effect
but do by themselves not fully determine treatment
response. In contrast, when diseases are highly heritable
but genetically complex, the predictive ability may not
come close to the theoretical maximum, because the
complexity hampers accurate assessment of the risks
associated with the specific combinations of variants.
Expected benefits of personal genome testing
The utility of personal genome testing is also determined
by the expected benefits for the individual who under-
goes testing. The range of potential benefits for genome
wide tests is broad and includes not only enabling deci-
sions about preventive or therapeutic interventions, but
also more subjective benefits such as enhancing motiva-
tion, making plans for the future, and simply knowing
one’s risks of disease. These subjective benefits of testing
have led to the recognition that in addition to clinical
and public health utility, there is personal utility that will
likely vary among consumers [12-14].
A challenge in the evaluation of the expected benefits is
the fact that genome-wide scans, and in the future also
w h o l eg e n o m es e q u e n c i n g ,a d d r e s sm u l t i p l ed i s e a s e sa t
the same time and typically are not advertised and ordered
for the prediction of one specific disease. This means that
the benefits of testing should be evaluated across all condi-
tions and traits that are tested, because it is not known in
advance for which disease one will benefit from testing.
This feature increases the utility of personal genome test-
ing, as by definition, the probability of carrying a mutation
or being at high risk for at least one disease is higher than
that for one specific disorder.
However, the expected benefits of testing not only
depend on what benefits may occur, but also on the
Figure 1 Relationship between the proportion of variance
explained by genetic factors and the maximum discriminative
accuracy of genetic testing. The discriminative accuracy, assessed as
the Area Under the receiver operating characteristic Curve (AUC), is the
extent to which predicted risks can discriminate between individuals
who will develop the disease of interest and those who will not. The
AUC is the probability that the test correctly identifies the person who
will develop the disease from a pair of whom one will be affected and
one will remain unaffected, and ranges from 0.5 (total lack of
discrimination) to 1.0 (perfect discrimination). The numbers next to the
smoothed lines refer to the risk of disease in the population. Reprinted
with permission from ref 7 (Copyright 2006, Wolters Kluwer Health).
Figure 2 Relationship between the heritability, genetic
complexity and predictive ability of personal genome testing.
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of testing may be higher when more diseases are tested
for, the likelihood of having at least some benefit may still
be quantitatively low. For example, 23andme tests three
mutations in BRCA1/2 of the thousands that have been
documented, but which are found solely among persons
from Ashkenazi Jewish descent. The probability that
women with no Ashkenazi Jewish roots will learn that
they have one of these mutations is virtually zero. Simi-
larly, many mutations for other monogenic traits are
specific to populations or families, implying that also indi-
viduals with a family history of disease may test negative
for documented mutations. Whole genome sequencing
will likely identify new mutations in these individuals, but
their impact on disease risk is unknown without evalua-
tion in other affected and non-affected relatives. Thus,
testing for rare variants with strong effects has little rele-
vance in the absence of family specific information. Predis-
position to drug responses is another example where
ap r i o r ithe expected benefits of testing are low, because
the probability of these benefits is conditional on develop-
ing an indication for the specific drug and the deleterious
gene variants may be population specific.
But also for complex diseases, the likelihood of bene-
fits may be disappointingly low. The presumed rationale
for learning about one’sr i s ki st h a te l e v a t e dr i s k sc a n
motivate to adopt a healthier lifestyle or other preven-
tive strategies, but genetic risk models with moderate
predictive ability are not able to distinguish sizeable sub-
groups with substantially elevated risks. For example, in
a large-population-based cohort the average risk of type
2 diabetes was 20% and the observed range of risks pre-
dicted by a model that included 18 low-risk susceptibil-
ity variants was 7 to 45% [15]. If this test were offered
by companies to consumers, approximately 5% of the
consumers would learn that their risks are higher than
30% but nobody that their risk are higher than 50%.
Hence, consumers who would only be motivated when
their genetic risks were at least 50% could have known
ap r i o r ithat this motivational benefit should not be
expected from this test. To learn whether personal gen-
ome testing might motivate, consumers should first ask
themselves what risk increase would make them change
their behavior and then see whether the test has suffi-
cient predictive ability to tell that risk. Because it is
argued that the key to the success of DTC companies is
clarity and transparency [14,16], consumers should have
insight in the expected benefits and the predictive ability
prior to purchasing.
Concluding remarks
Even though most direct-to-consumer companies are
still offering personal genome testing on the basis of
genome-wide scans, it is clear that this technique will be
outdated as soon as whole genome sequencing becomes
affordable to consumers. Standard genome-wide scans
will increasingly fail to cover the latest variants for the
prediction of complex diseases when whole genome
sequencing is used for variant discovery, and they do
not cover variants for monogenic traits. Whole genome
sequencing covers the entire DNA sequence, which
means that all DNA variations can be read including
common and rare variants implicated in monogenic and
complex outcomes.
For monogenic diseases, whole genome sequencing
w i l lh a v et h es a m ep r e d i c t i v ea b i l i t ya st e s t so fk n o w n
mutations that are currently conducted in the clinical
genetics practice. Whole genome sequencing can simul-
taneously test for many monogenic diseases, which
increases the likelihood that individuals might benefit
from knowing their DNA for at least one disease. This
feature of whole genome sequencing certainly contri-
butes to a strong sense of personal utility. However, in
the absence of a positive family history or early symp-
toms, the a priori probability of carrying a known muta-
tion will be low. At the same time, whole genome
sequencing will also reveal numerous mutations with
unknown impact that have never been seen before.
These unknown mutations are difficult to interpret.
High-throughput algorithms that combine information
from biology, bioinformatics, proteomics and population
genetics might be developed in the future to predict the
effect of the many variants encountered, but at present
one needs family, epidemiological or functional studies
to quantify the deleterious effect of such mutations.
For complex diseases, whole genome sequencing will
also certainly outperform prediction based on genome-
wide scans, because more variants are captured. Yet,
because complex diseases are only partly determined by
genetic variants or are genetically too complex, it should
not be expected that prediction of complex diseases
becomes markedly better. When the predictive ability
remains limited and prevention is effective even in the
absence of a genetically increased risk, the likelihood
that test results will lead to any benefit or intelligible
decisions at the a personal level, is very low.
Does this mean that whole genome sequencing will have
no utility at all? This is clearly not the case. There are many
tests in health care that have moderate predictive ability for
the individual, but these are found useful to make decisions
about prevention or treatment for larger groups of people.
Similarly, there will be numerous opportunities in health
care in which whole genome sequencing likely may be
implemented to improve health outcomes in patients and
populations; opportunities wher eam o d e r a t ep r e d i c t i v ea b i l -
ity is sufficient and the expected benefits are higher. Moder-
ate predictive ability may be sufficient in population-based
screening programs, such as breast cancer mammography
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to differentiate in starting age or frequency of monitoring
[17]. Expected benefits may be larger when tests are targeted
to specific at-risk populations, e.g., to identify the genetic
cause of congenital disorders in newborns, to search and
subsequently test private mutations in families with a posi-
tive history of hereditary disease, or to test predisposition to
specific drug responses upon indication of symptoms.
Undoubtedly, whole genome sequencing will be imple-
mented in health care when it leads to better health out-
comes for populations, even if at the personal level the
benefits are modest and many individuals receive a
wrong or unnecessary preventive or therapeutic inter-
vention. Health care payers will finance predictive tests
that benefit populations at large, but it is unlikely that
individual consumers will massively spend money on
expensive tests that have moderate predictive ability and
unclear personal benefits.
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